Corbus Pharmaceuticals Holdings, Inc.

NASDAQ•CRBP

CEO: Dr. Yuval Cohen Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2014-10-27

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

連絡先情報

500 River Ridge Drive, Norwood, MA, 02062, United States

617-963-0100

www.corbuspharma.com

時価総額

$117.96M

PER (TTM)

-1.6

17.9

配当利回り

52週高値

$20.56

52週安値

$4.64

52週レンジ

30%

順位65Top 96.0%

1.6

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 1.6 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$1.25+0.00%

直近4四半期の推移

フリーCF

-$15.93M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

CRB-701 Clinical Advancement CRB-701 data presented at ESMO25; FDA meeting planned Q1 2026 for HNSCC/cervical registration.

CRB-913 Obesity Trial Progress Phase 1a completed; Phase 1b CANYON-1 study initiated December 2025, completion expected Summer 2026.

R&D Spending Increased 118% R&D expense reached $70.1M USD in 2025, up 118% from $32.2M USD, focusing on pipeline advancement.

Cash Position Maintained Total cash, equivalents, investments stood at $163.3M USD as of December 31, 2025, supporting operations.

リスク要因

Net Loss Significantly Widened Net loss reached $78.5M USD in 2025, substantially increasing from $40.2M USD loss in prior year.

Continued Need for Capital Expect continued operating losses; substantial additional financing required to fund ongoing pre-clinical and clinical development.

Reliance on Third-Party Manufacturing Complete dependence on contract manufacturers for cGMP supply; failure risks halting development or commercialization efforts.

CRB-601 Program Deprioritized CRB-601 program deprioritized; company will not enroll additional patients in the Phase 1 dose escalation study.

見通し

Advance CRB-701 Regulatory Path Expect meeting with FDA in Q1 2026 to discuss clinical data and registrational study protocols for CRB-701.

Complete CRB-913 Phase 1b Study CANYON-1 Phase 1b dose-range finding study completion expected in Summer 2026 for obesity candidate.

Manage Operating Cash Runway Current cash ($163.3M USD) expected to fund operations for at least twelve months from filing date.

Maintain Nasdaq Listing Compliance Must satisfy Nasdaq continued listing requirements; failure risks delisting, impairing liquidity and financing ability.

同業比較

売上高 (TTM)

GNFT

$126.71M

+9.8%

CDXS

$70.39M

+18.6%

IVVD

$53.43M

+110.5%

粗利益率 (最新四半期)

GNFT

100.0%

+0.0pp

SGMO

100.0%

+0.0pp

APLT

100.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
GNFT	$445.68M	-10.9	-63.7%	64.1%
PEPG	$368.04M	-4.1	-75.7%	9.8%
FBRX	$334.97M	-9.2	-75.6%	0.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月4日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし